Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial

INTRODUCTION: The objective of this study was to demonstrate that BCD-057 is similar to innovator adalimumab (iADA) in terms of efficacy, safety, and pharmacokinetics in steady state in the target population of patients with moderate to severe plaque psoriasis (NCT02762955). METHODS: Patients were r...

Descripción completa

Detalles Bibliográficos
Autores principales: Samtsov, Alexey V., Bakulev, Andrey L., Khairutdinov, Vladislav R., Kokhan, Muza M., Korotaeva, Tat’yana V., Minullin, Iskander K., Vylegzhanina, Olga A., Dubenskiy, Valery V., Khalilov, Bulat V., Khotko, Alkes A., Zykova, Olga S., Chumachenko, Irina V., Lukyanov, Alexander M., Artemeva, Antonina V., Pukhtinskaia, Polina P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820628/
https://www.ncbi.nlm.nih.gov/pubmed/35130291
http://dx.doi.org/10.1371/journal.pone.0263214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820628/
https://www.ncbi.nlm.nih.gov/pubmed/35130291
http://dx.doi.org/10.1371/journal.pone.0263214

Ejemplares similares